» Articles » PMID: 35682953

Beyond Genetics: Metastasis As an Adaptive Response in Breast Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jun 10
PMID 35682953
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic disease represents the primary cause of breast cancer (BC) mortality, yet it is still one of the most enigmatic processes in the biology of this tumor. Metastatic progression includes distinct phases: invasion, intravasation, hematogenous dissemination, extravasation and seeding at distant sites, micro-metastasis formation and metastatic outgrowth. Whole-genome sequencing analyses of primary BC and metastases revealed that BC metastatization is a non-genetically selected trait, rather the result of transcriptional and metabolic adaptation to the unfavorable microenvironmental conditions which cancer cells are exposed to (e.g., hypoxia, low nutrients, endoplasmic reticulum stress and chemotherapy administration). In this regard, the latest multi-omics analyses unveiled intra-tumor phenotypic heterogeneity, which determines the polyclonal nature of breast tumors and constitutes a challenge for clinicians, correlating with patient poor prognosis. The present work reviews BC classification and epidemiology, focusing on the impact of metastatic disease on patient prognosis and survival, while describing general principles and current in vitro/in vivo models of the BC metastatic cascade. The authors address here both genetic and phenotypic intrinsic heterogeneity of breast tumors, reporting the latest studies that support the role of the latter in metastatic spreading. Finally, the review illustrates the mechanisms underlying adaptive stress responses during BC metastatic progression.

Citing Articles

Liquid biopsy for gastric cancer: Techniques, applications, and future directions.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L World J Gastroenterol. 2024; 30(12):1680-1705.

PMID: 38617733 PMC: 11008373. DOI: 10.3748/wjg.v30.i12.1680.


Breast cancers as ecosystems: a metabolic perspective.

Martino F, Lupi M, Giraudo E, Lanzetti L Cell Mol Life Sci. 2023; 80(9):244.

PMID: 37561190 PMC: 10415483. DOI: 10.1007/s00018-023-04902-9.


New approach methodologies to facilitate and improve the hazard assessment of non-genotoxic carcinogens-a PARC project.

Audebert M, Assmann A, Azqueta A, Babica P, Benfenati E, Bortoli S Front Toxicol. 2023; 5:1220998.

PMID: 37492623 PMC: 10364052. DOI: 10.3389/ftox.2023.1220998.


The Metastatic Process through the Eyes of Epigenetic Regulation: A Promising Horizon for Cancer Therapy.

Smolkova B, Earl J, Kataki A Int J Mol Sci. 2022; 23(24).

PMID: 36555088 PMC: 9778637. DOI: 10.3390/ijms232415446.


Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance.

Azam A, Sounni N Cancers (Basel). 2022; 14(24).

PMID: 36551752 PMC: 9776509. DOI: 10.3390/cancers14246267.

References
1.
Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E . SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012; 487(7407):380-4. DOI: 10.1038/nature11207. View

2.
Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

3.
Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

4.
Jackson H, Fischer J, Zanotelli V, Ali H, Mechera R, Soysal S . The single-cell pathology landscape of breast cancer. Nature. 2020; 578(7796):615-620. DOI: 10.1038/s41586-019-1876-x. View

5.
Leong K, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I . Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007; 204(12):2935-48. PMC: 2118507. DOI: 10.1084/jem.20071082. View